...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Promissory Notes

This is always a concern the way these two companies are run with no funds. We have been given no information to say they raised some cash and paid these off so we have to assume they are in effect. We haven't received the Q1/22 quarterly financials yet and they are due which might say they don't want to show them to us yet. They usually come out about the same time as the annuals that came out 3 weeks ago. The Newsoara portion is pretty common as RVX is always operating under threats like that. The DM and relative portion is quite concerning. He is taking steps so if he fails, he collects any scraps of the company even before Newsoara as his is secured and Newsoara's isn't unless there are changes we don't know about.

Share
New Message
Please login to post a reply